News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
The new hub, which brings Avantor solutions closer to regional customers and strengthens global supply chain capabilities, will be fully operational early next year
Subscribe To Our Newsletter & Stay Updated
